4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
InSilico Medicine Cayman TopCo (3696) operates in the Biotechnology industry and is headquartered in Hong Kong, Hong Kong with about 333 employees. Its market capitalization is roughly HK$35 billion. In the fiscal year ended 2025-12-31, 3696 reported $56M in revenue and ($352M) in net income.
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms.
Interactive charts & full statements → Open the 3696 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $56M | $86M | $51M | $30M |
| Gross Profit | $46M | $78M | $39M | $19M |
| Operating Income (EBIT) | ($62M) | ($33M) | ($90M) | ($80M) |
| Net Income | ($352M) | ($17M) | ($212M) | ($222M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $490M | $144M | $203M | $235M |
| Total Liabilities | $38M | $808M | $853M | $684M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 3696 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms